Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of “Moderate Buy” from Analysts

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has been assigned an average recommendation of “Moderate Buy” from the ten brokerages that are presently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, one has issued a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $6.8571.

NMRA has been the topic of several research reports. Guggenheim restated a “buy” rating and set a $14.00 price objective on shares of Neumora Therapeutics in a report on Tuesday, March 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neumora Therapeutics in a report on Tuesday, April 21st. Mizuho dropped their price target on Neumora Therapeutics from $6.00 to $4.00 and set an “outperform” rating on the stock in a research report on Thursday, June 18th. Needham & Company LLC cut their price target on Neumora Therapeutics from $8.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, June 16th. Finally, HC Wainwright decreased their price objective on Neumora Therapeutics from $18.00 to $7.00 and set a “buy” rating for the company in a report on Tuesday, June 16th.

Neumora Therapeutics Price Performance

Shares of NMRA stock opened at $1.67 on Monday. The company has a debt-to-equity ratio of 0.75, a current ratio of 5.09 and a quick ratio of 5.09. The company has a market capitalization of $309.42 million, a P/E ratio of -1.26 and a beta of 2.74. The company’s 50-day simple moving average is $1.80 and its two-hundred day simple moving average is $2.18. Neumora Therapeutics has a one year low of $0.78 and a one year high of $3.65.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.02. As a group, equities analysts anticipate that Neumora Therapeutics will post -0.93 EPS for the current year.

Institutional Trading of Neumora Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Siren L.L.C. boosted its holdings in shares of Neumora Therapeutics by 35.1% in the 1st quarter. Siren L.L.C. now owns 8,497,822 shares of the company’s stock valued at $16,571,000 after acquiring an additional 2,209,039 shares during the last quarter. Perceptive Advisors LLC purchased a new position in shares of Neumora Therapeutics during the first quarter worth $9,953,000. Millennium Management LLC lifted its holdings in shares of Neumora Therapeutics by 80.1% in the 4th quarter. Millennium Management LLC now owns 3,616,514 shares of the company’s stock valued at $6,474,000 after buying an additional 1,608,266 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Neumora Therapeutics by 24.2% in the 4th quarter. Renaissance Technologies LLC now owns 1,445,902 shares of the company’s stock valued at $2,588,000 after buying an additional 281,926 shares during the period. Finally, Ikarian Capital LLC boosted its stake in shares of Neumora Therapeutics by 10,128.9% in the fourth quarter. Ikarian Capital LLC now owns 1,278,408 shares of the company’s stock worth $2,288,000 after buying an additional 1,265,910 shares during the last quarter. 47.65% of the stock is currently owned by institutional investors and hedge funds.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.